Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma – appraisal consultation document

In this DRAFT guidance, lenalidomide is not recommended as cost-effectiveness estimates are uncertain due to limitations in the model which might not reflect what happens in the NHS in England.


National Institute for Health and Care Excellence